Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

David Meeker will inherit CEO job at Genzyme

This article was originally published in Scrip

Executive Summary

Sanofi has appointed David Meeker CEO of Genzyme, replacing Henri Termeer, effective 1 November 2011. He will report to Christopher Viehbacher, CEO of Sanofi and chair of Genzyme. Under Mr Meeker's leadership Genzyme plans to incorporate the rare disease business and the multiple sclerosis franchise. Mr Meeker has served at Genzyme since 1994, most recently as COO.

You may also be interested in...



Longtime Genzyme Holdout Meeker Passes Reigns To Sibold

Bill Sibold will take over the leadership of Sanofi's Cambridge-based Genzyme group as the unit begins the important launch of Dupixent. Meeker ends his career at Genzyme after 23 years.

Almirall launches Constella in six European markets

Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.

Dermira raises $35m in series B

Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.

Topics

Related Companies

UsernamePublicRestriction

Register

SC014948

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel